Avanos Medical (NYSE:AVNS) Issues FY 2025 Earnings Guidance

Avanos Medical (NYSE:AVNS) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 0.850-0.950 for the period, compared to the consensus EPS estimate of 0.850. The company issued revenue guidance of $690.0 million-$700.0 million, compared to the consensus revenue estimate of $679.6 million.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Wall Street Zen downgraded Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a research report on Tuesday, October 14th. Finally, Zacks Research upgraded shares of Avanos Medical to a “hold” rating in a research note on Tuesday, August 12th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Avanos Medical Price Performance

AVNS stock traded up $0.35 during midday trading on Thursday, reaching $11.01. The company had a trading volume of 457,140 shares, compared to its average volume of 542,663. The company has a market capitalization of $510.65 million, a price-to-earnings ratio of -1.09 and a beta of 1.19. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.64 and a quick ratio of 1.58. Avanos Medical has a 1-year low of $9.30 and a 1-year high of $21.12. The stock has a 50 day moving average price of $11.71 and a 200-day moving average price of $11.92.

Avanos Medical (NYSE:AVNS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.10. The business had revenue of $177.80 million for the quarter, compared to analyst estimates of $164.50 million. Avanos Medical had a negative net margin of 66.89% and a positive return on equity of 6.16%. The firm’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same quarter last year, the business posted $0.33 EPS. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Equities research analysts expect that Avanos Medical will post 1.32 earnings per share for the current year.

Insider Buying and Selling at Avanos Medical

In related news, Director Gary Blackford acquired 40,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 13th. The stock was acquired at an average cost of $10.99 per share, for a total transaction of $439,600.00. Following the completion of the acquisition, the director directly owned 40,000 shares of the company’s stock, valued at approximately $439,600. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 2.64% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Avanos Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after buying an additional 1,121 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Avanos Medical by 969.3% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after buying an additional 2,307 shares during the period. Jane Street Group LLC grew its stake in shares of Avanos Medical by 5.8% in the 2nd quarter. Jane Street Group LLC now owns 56,044 shares of the company’s stock valued at $686,000 after buying an additional 3,062 shares during the period. Tower Research Capital LLC TRC increased its position in Avanos Medical by 433.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,257 shares of the company’s stock valued at $77,000 after buying an additional 5,083 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Avanos Medical by 4.7% during the 2nd quarter. American Century Companies Inc. now owns 128,777 shares of the company’s stock worth $1,576,000 after buying an additional 5,830 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.